<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02337569</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-02-4</org_study_id>
    <nct_id>NCT02337569</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nobelpharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nobelpharma</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate efficacy and safety of NPC-02 in patients with
      Zinc Deficiency.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change amount of serum zinc concentration between starting and 8 weeks after dosing</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Zinc Deficiency</condition>
  <arm_group>
    <arm_group_label>NPC-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-02</intervention_name>
    <arm_group_label>NPC-02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The serum zinc concentrations are under the normal level before registration

        Exclusion Criteria:

          1. Heavy hepatitis

          2. Malignant tumor

          3. Severe heart disease, hematological disorder, kidney disease and pancreatic disease,
             etc.

          4. The serum albumin under 2.8 g/dL

          5. Patient of allergy and hyperesthesia to zinc containing medicine manufacturing
             (including supplement)

          6. Patient who was taking a medicine including the zinc (including supplement) within 12
             weeks before registration

          7. Pregnant, suspected pregnant, lactating, patients who wish to have a child

          8. Patient who participated in other clinical trials within 12 weeks before registration

          9. Unsuitable as a target of this clinical trial judged by doctor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Osaka Medical Center for Cancer and Cardiovascular Diseases</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 9, 2015</study_first_submitted>
  <study_first_submitted_qc>January 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

